133 related articles for article (PubMed ID: 27030518)
1. Prioritization of anticancer drugs against a cancer using genomic features of cancer cells: A step towards personalized medicine.
Gupta S; Chaudhary K; Kumar R; Gautam A; Nanda JS; Dhanda SK; Brahmachari SK; Raghava GP
Sci Rep; 2016 Mar; 6():23857. PubMed ID: 27030518
[TBL] [Abstract][Full Text] [Related]
2. Herceptin resistance database for understanding mechanism of resistance in breast cancer patients.
Ahmad S; Gupta S; Kumar R; Varshney GC; Raghava GP
Sci Rep; 2014 Mar; 4():4483. PubMed ID: 24670875
[TBL] [Abstract][Full Text] [Related]
3. Integrative and personalized QSAR analysis in cancer by kernelized Bayesian matrix factorization.
Ammad-ud-din M; Georgii E; Gönen M; Laitinen T; Kallioniemi O; Wennerberg K; Poso A; Kaski S
J Chem Inf Model; 2014 Aug; 54(8):2347-59. PubMed ID: 25046554
[TBL] [Abstract][Full Text] [Related]
4. Anticancer drug sensitivity prediction in cell lines from baseline gene expression through recursive feature selection.
Dong Z; Zhang N; Li C; Wang H; Fang Y; Wang J; Zheng X
BMC Cancer; 2015 Jun; 15():489. PubMed ID: 26121976
[TBL] [Abstract][Full Text] [Related]
5. Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance.
Shao W; Growney JD; Feng Y; O'Connor G; Pu M; Zhu W; Yao YM; Kwon P; Fawell S; Atadja P
Int J Cancer; 2010 Nov; 127(9):2199-208. PubMed ID: 20127862
[TBL] [Abstract][Full Text] [Related]
6. HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA).
Mehdi O; Françoise S; Sofia CL; Urs G; Kevin Z; Bernard S; Igor S; Anabela CD; Dominique L; Eric M; Ali O
Pancreatology; 2012; 12(2):146-55. PubMed ID: 22487525
[TBL] [Abstract][Full Text] [Related]
7. Improved anticancer drug response prediction in cell lines using matrix factorization with similarity regularization.
Wang L; Li X; Zhang L; Gao Q
BMC Cancer; 2017 Aug; 17(1):513. PubMed ID: 28768489
[TBL] [Abstract][Full Text] [Related]
8. Genetic load makes cancer cells more sensitive to common drugs: evidence from Cancer Cell Line Encyclopedia.
Pavel AB; Korolev KS
Sci Rep; 2017 May; 7(1):1938. PubMed ID: 28512298
[TBL] [Abstract][Full Text] [Related]
9. Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization.
Fischer C; Leithner K; Wohlkoenig C; Quehenberger F; Bertsch A; Olschewski A; Olschewski H; Hrzenjak A
Mol Cancer; 2015 Jan; 14():4. PubMed ID: 25608569
[TBL] [Abstract][Full Text] [Related]
10. Prediction of anticancer molecules using hybrid model developed on molecules screened against NCI-60 cancer cell lines.
Singh H; Kumar R; Singh S; Chaudhary K; Gautam A; Raghava GP
BMC Cancer; 2016 Feb; 16():77. PubMed ID: 26860193
[TBL] [Abstract][Full Text] [Related]
11. Identifying anti-cancer drug response related genes using an integrative analysis of transcriptomic and genomic variations with cell line-based drug perturbations.
Sun Y; Zhang W; Chen Y; Ma Q; Wei J; Liu Q
Oncotarget; 2016 Feb; 7(8):9404-19. PubMed ID: 26824188
[TBL] [Abstract][Full Text] [Related]
12. Activity of 2-aryl-2-(3-indolyl)acetohydroxamates against drug-resistant cancer cells.
Aksenov AV; Smirnov AN; Magedov IV; Reisenauer MR; Aksenov NA; Aksenova IV; Pendleton AL; Nguyen G; Johnston RK; Rubin M; De Carvalho A; Kiss R; Mathieu V; Lefranc F; Correa J; Cavazos DA; Brenner AJ; Bryan BA; Rogelj S; Kornienko A; Frolova LV
J Med Chem; 2015 Mar; 58(5):2206-20. PubMed ID: 25671501
[TBL] [Abstract][Full Text] [Related]
13. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.
Sonnemann J; Gänge J; Pilz S; Stötzer C; Ohlinger R; Belau A; Lorenz G; Beck JF
BMC Cancer; 2006 Jul; 6():183. PubMed ID: 16834771
[TBL] [Abstract][Full Text] [Related]
14. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.
Ibanez de Caceres I; Cortes-Sempere M; Moratilla C; Machado-Pinilla R; Rodriguez-Fanjul V; Manguán-García C; Cejas P; López-Ríos F; Paz-Ares L; de CastroCarpeño J; Nistal M; Belda-Iniesta C; Perona R
Oncogene; 2010 Mar; 29(11):1681-90. PubMed ID: 20023704
[TBL] [Abstract][Full Text] [Related]
15. Explainable drug sensitivity prediction through cancer pathway enrichment.
Tang YC; Gottlieb A
Sci Rep; 2021 Feb; 11(1):3128. PubMed ID: 33542382
[TBL] [Abstract][Full Text] [Related]
16. Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations.
Györffy B; Surowiak P; Kiesslich O; Denkert C; Schäfer R; Dietel M; Lage H
Int J Cancer; 2006 Apr; 118(7):1699-712. PubMed ID: 16217747
[TBL] [Abstract][Full Text] [Related]
17. A gene expression database for the molecular pharmacology of cancer.
Scherf U; Ross DT; Waltham M; Smith LH; Lee JK; Tanabe L; Kohn KW; Reinhold WC; Myers TG; Andrews DT; Scudiero DA; Eisen MB; Sausville EA; Pommier Y; Botstein D; Brown PO; Weinstein JN
Nat Genet; 2000 Mar; 24(3):236-44. PubMed ID: 10700175
[TBL] [Abstract][Full Text] [Related]
18. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
[TBL] [Abstract][Full Text] [Related]
19. Establishment and characterization of cell lines from chromosomal instable colorectal cancer.
Maletzki C; Gock M; Randow M; Klar E; Huehns M; Prall F; Linnebacher M
World J Gastroenterol; 2015 Jan; 21(1):164-76. PubMed ID: 25574089
[TBL] [Abstract][Full Text] [Related]
20. Human B-cell cancer cell lines as a preclinical model for studies of drug effect in diffuse large B-cell lymphoma and multiple myeloma.
Laursen MB; Falgreen S; Bødker JS; Schmitz A; Kjeldsen MK; Sørensen S; Madsen J; El-Galaly TC; Bøgsted M; Dybkær K; Johnsen HE;
Exp Hematol; 2014 Nov; 42(11):927-38. PubMed ID: 25072621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
